The DNA Sequencing & Genomics Facility provides access to state-of-the-art fluorescent DNA sequencing technology for all Cancer Center members. The goal of the sequencing facility is to provide high quality, low cost DNA sequencing with a rapid turnaround time of 2-3 working days. To accomplish this, the facility uses Prism 377 automated sequencers (PE Applied Biosystems), equipped with the most advanced hardware and software upgrades to produce the quality and accuracy necessary to satisfy the need of the researchers. The newest applications are constantly assessed and introduced into the core facility protocols to further enhance the quality of the research and the throughput of the facility. DNA templates provides by the users are sequenced using the powerful BigDye terminator chemistry. This new dye technology allows the facility to generate sequence from a wide variety of templates, including single and double stranded plasmids, PCR products and especially larger templates such as BAC, PAC and P1 clones. Primer walking and contig assembly projects are handled with minimum intervention on the part of the researcher. Consultation is available for experimental design, protocol definition, troubleshooting and education. The Genomics services are focused on PCR-based DNA fragment analysis. This includes the optimization of new fluorescently- tagged primers, PCR amplification of client-supported substrates in a 96-well format, multiplexing PCR products, sizing (and sometimes quantifying) products using the ABI 373 instrument, and scoring genotypes with the ABI Genotyper software. The Supervisors consult with researchers to develop appropriate strategies for rapid turnaround and high quality data at a minimum cost.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA042014-13
Application #
6334943
Study Section
Project Start
2000-07-25
Project End
2001-04-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
13
Fiscal Year
2000
Total Cost
$84,684
Indirect Cost
Name
University of Utah
Department
Type
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Zeng, Tao; Fleming, Aaron M; Ding, Yun et al. (2018) Nanopore Analysis of the 5-Guanidinohydantoin to Iminoallantoin Isomerization in Duplex DNA. J Org Chem 83:3973-3978
Himbert, Caroline; Ose, Jennifer; Nattenmüller, Johanna et al. (2018) Body fatness, adipose tissue compartments and biomarkers of inflammation and angiogenesis in colorectal cancer: the ColoCare Study. Cancer Epidemiol Biomarkers Prev :
Madison, Bethany J; Clark, Kathleen A; Bhachech, Niraja et al. (2018) Electrostatic repulsion causes anticooperative DNA binding between tumor suppressor ETS transcription factors and JUN-FOS at composite DNA sites. J Biol Chem 293:18624-18635
Arbeeva, Liubov S; Hanson, Heidi A; Arbeev, Konstantin G et al. (2018) How Well Does the Family Longevity Selection Score Work: A Validation Test Using the Utah Population Database. Front Public Health 6:277
Patel, Ami B; Lange, Thoralf; Pomicter, Anthony D et al. (2018) Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib. Oncotarget 9:17889-17894
De, Shrutokirti; Van Deren, Donn; Peden, Eric et al. (2018) Two distinct ontogenies confer heterogeneity to mouse brain microglia. Development 145:
Giraddi, Rajshekhar R; Chung, Chi-Yeh; Heinz, Richard E et al. (2018) Single-Cell Transcriptomes Distinguish Stem Cell State Changes and Lineage Specification Programs in Early Mammary Gland Development. Cell Rep 24:1653-1666.e7
Doherty, Jennifer A; Grieshober, Laurie; Houck, John R et al. (2018) Telomere Length and Lung Cancer Mortality among Heavy Smokers. Cancer Epidemiol Biomarkers Prev 27:829-837
Wagner, Alex H; Devarakonda, Siddhartha; Skidmore, Zachary L et al. (2018) Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. Nat Commun 9:3787
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551

Showing the most recent 10 out of 1193 publications